Ferro M, et al. - By analyzing relevant randomized trials published during the last 15 years, researchers investigated whether an increased incidence of fatigue may be relative to chronic use of corticosteroids in patients with prostate cancer. These studies involved patients with prostate cancer on systemic treatment. They analyzed prospective randomized phase 2 and 3 trials, with 22,734 men evaluable for fatigue. As per findings, 30.89% was the estimated pooled incidence of grade 1–2 fatigue; estimated pooled incidence of grade 3–4 fatigue was 3.90%. Patients who consumed daily corticosteroids as a component of their anti-neoplastic therapy had grade 3-4 fatigue nearly twice as often as that experienced by those who did not receive daily corticosteroids. To assess risk/benefit profile of low-dose, daily corticosteroids as part of systemic therapy, ad hoc-designed prospective clinical trials are required.